Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

MAP completes SPA with FDA for phase III clinical trial of MAP-0004 for migraine

Jan. 18, 2008

Neuroprotective effects of phosphorylated PRAS40 after spinal cord injury

Jan. 18, 2008

Recent patents describe novel analgesic agents

Jan. 17, 2008

Summit's lead drug candidate, SMT-D001, enters phase II clinical trials

Jan. 17, 2008

Gabriel Sciences receives grant from NIH for development of lead antidepressant compound

Jan. 17, 2008

Allon initiates phase I clinical trial of AL-108 and AL-208

Jan. 17, 2008

Data support therapeutic role for buprenorphine in neuropathic pain

Jan. 17, 2008

Pozen submits human lymphocyte study for Treximet to the FDA

Jan. 16, 2008

NDA filed for Keppra XR extended-release tablets

Jan. 16, 2008

Amkor's stroke drug nears end of phase I and prepares for phase II in 2008

Jan. 16, 2008

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
RX-10616 improves radiotherapy efficacy in HNSCC
BioWorld Science
Head and neck squamous cell carcinoma (HNSCC) accounts for high number of new diagnoses each year. Current management is based on surgery followed by radiotherapy...
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...